Advertisement

Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 798–799 | Cite as

ASO Author Reflections: Use of Retrospective Administrative Datasets in Rare Cancer Subtypes to Determine the Efficacy of Adjuvant Therapy

  • Ibrahim Nassour
  • Adam C. YoppEmail author
ASO Author Reflections

Notes

Disclosures

The authors have no conflicts of interest to disclose.

References

  1. 1.
    Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685–95.CrossRefGoogle Scholar
  2. 2.
    Gemox versus surveillance following surgery of localized biliary tract cancer: results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. In: 2017 gastrointestinal cancers symposium abstracts. 1–2. 2017.Google Scholar
  3. 3.
    Primrose JN, Fox R, Palmer DH, Prasad R, Mirza D, Anthoney DA, et al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. J Clin Oncol. 2017.  https://doi.org/10.1200/jco.2017.35.15_suppl.4006.Google Scholar
  4. 4.
    Nassour I, Mokdad AA, Porembka MR, Choti MA, Polanco PM, Mansour JC, et al. Adjuvant therapy is associated with improved survival in resected perihilar cholangiocarcinoma: a propensity matched study. Ann Surg Oncol. 2018;25:1193–201.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Division of Surgical Oncology, Department of SurgeryUniversity of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations